Acute Thrombotic Thrombocytopenic Purpura: Rare and Life-Threatening Side Effect of Recent BNT-162b2 COVID-19 Vaccination

HCA Healthc J Med. 2022 Dec 30;3(6):343-348. doi: 10.36518/2689-0216.1384. eCollection 2022.

Abstract

Description Thrombotic thrombocytopenic purpura (TTP) is a rare, potentially life-threatening disorder characterized by uncontrolled and spontaneous clot formation throughout the body. Known secondary causes of TTP include malignancy, bone marrow transplantation, pregnancy, various medications, and HIV infection. TTP in the setting of COVID-19 vaccination is rare and not well reported. Reported cases have been confined primarily to the AstraZeneca and Johnson and Johnson COVID-19 Vaccines. TTP in the setting of Pfizer BNT-162b2 vaccination has only recently been reported. We present a patient with no obvious risk factors for TTP who presented with acute altered mental status and was found to have objective evidence of TTP. To our knowledge, there are very few reported cases of TTP in the setting of a recent Pfizer COVID-19 vaccination.

Keywords: BNT-162b2; BNT162 vaccines; COVID-19 vaccines; SARS-CoV-2; TTP; drug-related side effects and adverse reactions; idiopathic thrombocytopenic purpura; thrombotic thrombocytopenia; thrombotic thrombocytopenic purpura.

Publication types

  • Case Reports

Grants and funding

This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare affiliated entity.